{"id":4903,"date":"2023-06-19T22:40:34","date_gmt":"2023-06-19T14:40:34","guid":{"rendered":"http:\/\/dh.oncolab.cn\/index.php\/2023\/06\/19\/%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac21%e7%ab%a0%ef%bc%9apd-1%e9%98%bb%e6%96%ad%e5%9c%a8%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%ad%e7%9a%84%e4%bd%9c%e7%94%a8%ef%bc%88%e4%b8%8b\/"},"modified":"2023-06-19T22:40:34","modified_gmt":"2023-06-19T14:40:34","slug":"%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac21%e7%ab%a0%ef%bc%9apd-1%e9%98%bb%e6%96%ad%e5%9c%a8%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%ad%e7%9a%84%e4%bd%9c%e7%94%a8%ef%bc%88%e4%b8%8b","status":"publish","type":"post","link":"http:\/\/dh.oncolab.cn\/index.php\/2023\/06\/19\/%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac21%e7%ab%a0%ef%bc%9apd-1%e9%98%bb%e6%96%ad%e5%9c%a8%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%ad%e7%9a%84%e4%bd%9c%e7%94%a8%ef%bc%88%e4%b8%8b\/","title":{"rendered":"\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c21\u7ae0\uff1aPD-1\u963b\u65ad\u5728\u80be\u7ec6\u80de\u764c\u4e2d\u7684\u4f5c\u7528\uff08\u4e0b\uff09"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n

\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c21\u7ae0\uff1aPD-1\u963b\u65ad\u5728\u80be\u7ec6\u80de\u764c\u4e2d\u7684\u4f5c\u7528\uff08\u4e0a\uff09<\/a><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

21.4 PD-L1\u4f5c\u4e3a\u9884\u6d4b\u751f\u7269\u6807\u5fd7\u7269<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u7531\u4e8e\u5bf9nivolumab\u7684\u5e94\u7b54\u7387\u7ea6\u4e3a25%\uff0c\u56e0\u6b64\u9700\u8981\u9884\u6d4b\u6027\u751f\u7269\u6807\u5fd7\u7269\u6765\u786e\u5b9a\u54ea\u4e9b\u60a3\u8005\u6700\u6709\u53ef\u80fd\u4ece\u6cbb\u7597\u4e2d\u53d7\u76ca\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u548c\u9cde\u72b6\u7ec6\u80de\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e2d\uff0cPD-L1\u7684\u8868\u8fbe\u4e0e\u63a5\u53d7nivolumab\u6216pembrolizumab\u6cbb\u7597\u7684\u60a3\u8005\u7684\u9884\u540e\u6539\u5584\u6709\u5173\u3002<\/p>\n

PD-L1\u751f\u7269\u6807\u5fd7\u7269\u7684\u7814\u7a76\u5df2\u7eb3\u5165\u80be\u764c\u4e34\u5e8a\u8bd5\u9a8c\u3002\u5728\u63a5\u53d7nivolumab\u6cbb\u7597\u7684296\u4f8b\u4e0d\u540c\u80bf\u7624\u60a3\u8005\u7684I\u671f\u8bd5\u9a8c\u4e2d\uff0c\u5206\u6790\u4e8642\u4e2a\u80bf\u7624(5\u4e2a\u80be\u764c)\u4e2dPD-L1\u7ec6\u80de\u8868\u9762\u7684\u8868\u8fbe\u3002\u514d\u75ab\u7ec4\u7ec7\u5316\u5b66(IHC)\u67d3\u8272\u9633\u6027\u7684\u7ec6\u80de\u4ee3\u8868\u5176PD-L1\u8868\u8fbe\u9633\u6027\u3002\u603b\u4f53\u800c\u8a00\uff0c\u8fd9\u4e9b\u6837\u672c\u4e2d\u670960%\u7684PD-L1\u8868\u8fbe\u9633\u6027\uff0c\u8fd9\u4e9b\u9633\u6027\u60a3\u8005\u4e2d\u670936%\u6709\u5ba2\u89c2\u53cd\u5e94\u3002\u5728PD-L1\u9634\u6027\u60a3\u8005\u4e2d\u6ca1\u6709\u89c2\u5bdf\u5230\u5ba2\u89c2\u53cd\u5e94\u3002<\/p>\n

\u5728\u63a5\u53d7\u4e0d\u540c\u5242\u91cfnivolumab\u6cbb\u7597\u7684\u80be\u764c\u60a3\u8005\u7684\u968f\u673aII\u671f\u8bd5\u9a8c\u4e2d\uff0c\u4f7f\u7528IHC\u6cd5\u6d4b\u5b9aPD-L1\u7684\u8868\u8fbe\u3002PD-L1\u8868\u8fbe\u9633\u6027\u7684\u622a\u6b62\u70b9\u4e3a5%\u7684\u80bf\u7624\u7ec6\u80de\u819c\u6027\u67d3\u8272\u3002\u5728107\u4f8b(64%)\u80bf\u7624\u8868\u8fbePD-L1\u7684\u60a3\u8005\u4e2d\uff0c29\u4f8b(27%)\u57285%\u7684\u80bf\u7624\u7ec6\u80de\u4e2d\u8868\u8fbePD-L1\uff0c78\u4f8b(73%)\u5728<5%\u7684\u80bf\u7624\u7ec6\u80de\u4e2d\u8868\u8fbePD-L1\u3002PD-L1\u9633\u6027\u60a3\u8005\u548cPD-L1\u9634\u6027\u60a3\u8005\u5728PD-L1\u8868\u8fbe\u9608\u503c\u4e3a1%\u65f6\u7684\u9884\u540e\u6ca1\u6709\u663e\u8457\u5dee\u5f02\u3002<\/p>\n

PD-L1\u7684\u5355\u72ec\u8868\u8fbe\u53ef\u80fd\u4e0e\u63a5\u53d7\u6297PD-1\u6cbb\u7597\u7684\u60a3\u8005\u7684\u9884\u540e\u6539\u5584\u6709\u5173\u3002\u5728\u6bd4\u8f83nivolumab\u548ceverolimus\u7684III\u671f\u8bd5\u9a8c\u4e2d\uff0cnivolumab\u7ec4\u7684410\u540d\u60a3\u8005\u4e2d\u6709370\u540d(90%)\u548c411\u540devolimus\u60a3\u8005\u4e2d\u7684386\u540d(94%)\u6709\u53ef\u91cf\u5316\u7684PD-L1\u8868\u8fbe\u3002\u5728PD-L1\u8868\u8fbe\u4e3a1%\u7684\u60a3\u8005\u4e2d\uff0cnivolumab\u7ec4\u60a3\u8005\u7684mOS\u4e3a21.8\u4e2a\u6708\uff0ceverolimus\u7ec4\u60a3\u8005\u4e3a18.8\u4e2a\u6708\u3002\u7136\u800c\uff0c\u5728PD-L1\u8868\u8fbe\u4f4e\u4e8e1%\u7684\u60a3\u8005\u4e2d\uff0cnivolumab\u548ceverolimus\u7ec4\u7684\u4e2d\u4f4dOS\u5206\u522b\u4e3a27.4\u4e2a\u6708\u548c21.2\u4e2a\u6708\u3002\u56e0\u6b64\uff0cPD-L1\u7684\u9ad8\u8868\u8fbe\u9884\u793a\u7740\u8f6c\u79fb\u6027\u80be\u7ec6\u80de\u764c\u60a3\u8005\u9884\u540e\u8f83\u5dee\uff0c\u800c\u4e0d\u80fd\u4f5c\u4e3a\u9884\u6d4b\u7597\u6548\u7684\u751f\u7269\u6807\u5fd7\u7269\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6700\u8fd1\u7684\u4e24\u9879\u56de\u987e\u6027\u5206\u6790\u7814\u7a76\u4e86\u80be\u764c\u4e2dPD-1\u8868\u8fbe\u7684\u9884\u540e\u548c\u9884\u6d4b\u4f5c\u7528\u3002\u524d\u4e00\u9879\u7814\u7a76\u663e\u793aPD-L1\u9ad8\u8868\u8fbe\u5bf9\u9884\u540e\u6709\u8d1f\u9762\u5f71\u54cd\uff0c\u6b7b\u4ea1\u98ce\u9669\u589e\u52a053%(HR 1.53\uff1b95% CI 1.27-1.84\uff1bp\u503c<0.001)\uff0c\u800c\u5728\u8f6c\u79fb\u6027\u80bf\u7624\u4e2d\uff0c\u539f\u53d1\u7076PD-L1\u8868\u8fbe\u4fdd\u7559\u4e86\u5176\u9884\u540e\u4f5c\u7528(HR1.45\uff1b95% CI 1.08-1.93\uff1bp\u503c0.01)\u3002\u7b2c\u4e8c\u9879\u7814\u7a76PD-L1\u8868\u8fbe\u7684\u53cd\u5e94\u6ca1\u6709\u4efb\u4f55\u5dee\u5f02\u3002<\/p>\n

\u7efc\u4e0a\u6240\u8ff0\uff0c\u6ca1\u6709\u8bc1\u636e\u8868\u660ePD-L1\u7684\u8868\u8fbe\u53ef\u4ee5\u4f5c\u4e3a\u63a5\u53d7nivolumab\u6cbb\u7597\u7684\u665a\u671f\u80be\u764c\u60a3\u8005\u7684\u9884\u6d4b\u751f\u7269\u6807\u8bb0\u7269\u3002\u8fd8\u9700\u8981\u4f7f\u7528\u66ff\u4ee3\u6297\u4f53\u5bf9PD-L1\u8fdb\u884c\u67d3\u8272\uff0c\u4ee5\u53ca\u5bf9\u989d\u5916\u7684\u7ec6\u80de\u7fa4(\u4f8b\u5982\uff0c\u6d78\u6da6\u6027\u514d\u75ab\u7ec6\u80de)\u8fdb\u884c\u67d3\u8272\uff0c\u4ee5\u786e\u5b9aPD-1\/PD-L1\u5728\u80be\u764c\u4e2d\u8868\u8fbe\u7684\u9884\u6d4b\u4ef7\u503c\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

21.5 PD-1\u5728\u80be\u764c\u4e2d\u7684\u5e94\u7528\u524d\u666f<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u7531\u4e8e\u5355\u836fnivolumab\u7684\u7814\u7a76\u53d6\u5f97\u4e86\u4ee4\u4eba\u9f13\u821e\u7684\u7ed3\u679c\uff0c\u7814\u7a76PD-1\u963b\u65ad\u7684\u8bd5\u9a8c\u8d8a\u6765\u8d8a\u591a\u3002\u5176\u4ed6\u68c0\u67e5\u70b9\u6291\u5236\u5242\u4e5f\u6b63\u5728\u79ef\u6781\u7814\u7a76\u4e2d\uff0c\u5305\u62ecpembrolizumab(\u6297PD-1)\u3001atezolizumab\u548cavelumab(\u4e24\u79cd\u6297PD-L1)\uff0c\u4ee5\u53caPD-1\/PD-L1\u6291\u5236\u5242\u4e0e\u5176\u4ed6\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u6216TKI\u7684\u8054\u5408\u7b56\u7565\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4e0e\u5355\u72ec\u6291\u5236PD-1\/PD-L1\u901a\u8def\u76f8\u6bd4\uff0c\u8054\u5408\u6cbb\u7597\u6709\u53ef\u80fd\u6539\u5584\u9884\u540e\u3002\u8003\u8651\u5230\u591a\u4e2a\u514d\u75ab\u68c0\u67e5\u70b9\u8c03\u8282\u7684\u590d\u6742\u6027\uff0c\u6240\u4ee5\u652f\u6301\u7ed3\u5408\u514d\u75ab\u6cbb\u7597\u7b56\u7565\u4ee5\u6700\u5927\u9650\u5ea6\u5730\u63d0\u9ad8\u4e34\u5e8a\u6548\u76ca\u662f\u5408\u7406\u7684\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4e8b\u5b9e\u4e0a\uff0cPD-1\u548cCTLA-4\u5728\u8c03\u8282\u83b7\u5f97\u6027\u514d\u75ab\u65f6\u4f3c\u4e4e\u626e\u6f14\u7740\u622a\u7136\u4e0d\u540c\u7684\u4e92\u8865\u89d2\u8272\u3002CTLA-4\u5728T\u7ec6\u80de\u6fc0\u6d3b\u540e\u65e9\u671f\u4e0a\u8c03\uff0c\u4ee5\u6291\u5236T\u7ec6\u80de\u529f\u80fd\uff0c\u800cPD-1\u5bfc\u81f4T\u7ec6\u80de\u65e0\u80fd\u548c\u8870\u7aed\u3002<\/p>\n

\u4e34\u5e8a\u524d\u7814\u7a76\u8868\u660e\uff0cPD-1\u548cCTLA-4\u53d7\u4f53\u963b\u65ad\u5242\u8054\u5408\u5e94\u7528\u53ef\u589e\u52a0\u6548\u5e94\u6027T\u7ec6\u80de\u7684\u6d78\u6da6\uff0c\u51cf\u5c11\u8c03\u8282\u6027T\u7ec6\u80de\u7684\u6d78\u6da6\uff0c\u589e\u52a0\u5e72\u6270\u7d20-\u03d2\u7684\u4ea7\u751f\uff0c\u4ece\u800c\u4ea7\u751f\u66f4\u663e\u8457\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002 <\/p>\n

\u5728I\u671f\u8bd5\u9a8c\u4e2d\uff0c\u5bf944\u4f8b\u80be\u764c\u60a3\u8005\u4f7f\u7528\u4e0d\u540c\u5242\u91cf(nivolumab 3 mg\/kg+ipilimumab 1 mg\/kg\uff0c\u6bcf3\u5468\u00d74\u5242\uff0cnivolumab 1 mg\/kg+ipilimumab 3 mg\/kg\uff0c\u6bcf3\u5468\u00d74\u5242\uff0c\u7136\u540e\u6bcf2\u5468\u8fde\u7eed\u670d\u7528nivolumab 3 mg\/kg)\u7684\u836f\u7269\u6765\u8bc4\u4f30nivolumab\u4e0e\u6297CTLA-4\u7684\u5b8c\u5168\u4eba\u6e90\u5316IgG1\u6297\u4f53ipilimumab\u7684\u8054\u5408\u5e94\u7528\u3002 <\/p>\n

18%\u7684\u60a3\u8005\u56e0\u6cbb\u7597\u4ea7\u751f\u76f8\u5173\u7684\u4e0d\u826f\u53cd\u5e94\uff0c\u5305\u62ec\u80ba\u708e\u3001\u8179\u6cfb\u3001\u6dc0\u7c89\u9176\/\u8102\u80aa\u9176\u548c\u4e19\u6c28\u9178\u8f6c\u6c28\u9176\u5347\u9ad8\u800c\u505c\u6b62\u6cbb\u7597\u3002\u4e24\u4e2a\u6cbb\u7597\u7ec4\u7684ORR\u5747\u4e3a45%\uff0c\u4e14\u5f88\u9ad8\u6bd4\u4f8b(80%)\u7684\u60a3\u8005\u6709\u6301\u7eed\u53cd\u5e94\u3002\u8fd9\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u7ed3\u679c\u5f15\u5bfc\u4e86\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684III\u671f\u8bd5\u9a8c\uff0c\u5c06\u8fd9\u79cd\u8054\u5408\u7597\u6cd5\u4e0esunitinib\uff08\u8212\u5c3c\u66ff\u5c3c\uff09\u4f5c\u4e3amRCC\u7684\u4e00\u7ebf\u6cbb\u7597\u8fdb\u884c\u6bd4\u8f83\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53c2\u4e0e\u4e86\u9ad3\u7cfb\u6291\u5236\u7ec6\u80de\u7684\u53d1\u80b2\u548c\u8c03\u63a7\uff0c\u800c\u8212\u5c3c\u66ff\u5c3c\u901a\u8fc7\u51cf\u5c11\u9ad3\u7cfb\u6291\u5236\u7ec6\u80de\u800c\u9006\u8f6c\u80bf\u7624\u8bf1\u5bfc\u7684\u514d\u75ab\u6291\u5236\u3002\u8fd9\u79cd\u51cf\u5c11\u4e0e\u6548\u5e94\u5668T\u7ec6\u80de\u529f\u80fd\u7684\u6539\u5584\u548cT\u7ec6\u80de\u5e72\u6270\u7d20-\u03b3\u7684\u4ea7\u751f\u4ee5\u53ca\u8c03\u8282\u6027T\u7ec6\u80de\u6570\u91cf\u7684\u4e0b\u964d\u6709\u5173\u3002<\/p>\n

\u5176\u4ed6\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u6291\u5236\u5242\u5df2\u7ecf\u663e\u793a\u51fa\u901a\u8fc7\u8bf1\u5bfc\u81ea\u566c\u548c\u6291\u5236\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de\u7684\u6fc0\u6d3b\u6765\u589e\u5f3a\u514d\u75ab\u7cfb\u7edf\u7684\u80fd\u529b\uff0c\u8fd9\u4e0e\u80be\u764c\u4e2d\u7684\u80bf\u7624\u5fae\u8840\u7ba1\u5bc6\u5ea6\u548c\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u6c34\u5e73\u76f8\u5173\u3002<\/p>\n

\u6b64\u5916\uff0c\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u80fd\u591f\u663e\u8457\u5f71\u54cd\u6811\u7a81\u72b6\u7ec6\u80de\u7684\u529f\u80fd\u6210\u719f\uff0c\u6811\u7a81\u72b6\u7ec6\u80de\u662f\u8bf1\u5bfc\u521d\u7ea7\u514d\u75ab\u53cd\u5e94\u7684\u6700\u6709\u6548\u7684APC\u3002\u8fd9\u4e9b\u7ed3\u679c\u8868\u660e\uff0c\u6291\u5236\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u4e0d\u4ec5\u53ef\u4ee5\u6291\u5236\u8840\u7ba1\u751f\u6210\uff0c\u8fd8\u53ef\u4ee5\u63d0\u9ad8\u6297\u539f\u63d0\u5448\u7684\u529f\u80fd\u6548\u529b\uff0c\u4ece\u800c\u6709\u52a9\u4e8e\u6297\u80bf\u7624\u7ec6\u80de\u81ea\u8eab\u514d\u75ab\u7684\u53d1\u5c55\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u8003\u8651\u5230\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u7684\u6291\u5236\u548cPD-1\/PD-L1\u963b\u65ad\u76f8\u7ed3\u5408\u7684\u4e34\u5e8a\u524d\u7406\u8bba\uff0c\u4e00\u9879I\u671f\u8bd5\u9a8c\u7814\u7a76\u4e86\u5728\u8f6c\u79fb\u6027\u80be\u7ec6\u80de\u764c\u60a3\u8005\u4e2d\u9012\u589e\u5242\u91cf\u7684nivolumab(2 mg\/kg\u5242\u91cf\u6bcf3\u5468\u589e\u52a0\u52305 mg\/kg)\u4e0esunitinib(\u6bcf\u592950 mg\uff0c\u670d\u75284\u5468\uff0c\u505c\u836f2\u5468\uff1b33\u540d\u60a3\u8005)\u6216 pazopanib(\u6bcf\u5929800 mg\uff0c22\u540d\u60a3\u8005)\u7684\u7ec4\u5408\u3002<\/p>\n

\u5c3d\u7ba1pazopanib\u7ec4\u7684\u7814\u7a76\u7531\u4e8e\u5242\u91cf\u9650\u5236\u7684\u809d\u810f\u6bd2\u6027\u800c\u505c\u6b62\uff0c\u4f46sunitinib\u8054\u5408\u7ec4\u7684\u5242\u91cf\u589e\u52a0\u5230\u6bd4nivolumab\u66f4\u9ad8\u7684\u5242\u91cf\uff0c\u5e76\u5c06\u7597\u6548\u6269\u5927\u5230\u672a\u63a5\u53d7\u6cbb\u7597\u7684\u60a3\u8005\u3002<\/p>\n

\u63a5\u53d7nivolumab\u548csunitinib\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\u670982%\u89c2\u5bdf\u5230\u4e0e\u6cbb\u7597\u76f8\u5173\u76843-4\u7ea7\u4e0d\u826f\u53cd\u5e94\uff0c\u800c\u63a5\u53d7nivolumab\u548cpazopanib\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\u670970%\u89c2\u5bdf\u5230\u4e0e\u6cbb\u7597\u76f8\u5173\u7684\u4e0d\u826f\u53cd\u5e94\u3002\u603b\u4f53\u800c\u8a00\uff0c\u670d\u7528sunitinib\u7684\u60a3\u8005\u4e2d\u670936%\u7684\u60a3\u8005\u548c\u670d\u7528pazopanib\u7684\u60a3\u8005\u4e2d\u670925%\u7684\u60a3\u8005\u56e0\u4e0d\u826f\u4e8b\u4ef6\u800c\u505c\u6b62\u6cbb\u7597\u3002<\/p>\n

sunitinib\u7ec4\u548cpazopanib\u7ec4\u7684ORR\u5206\u522b\u4e3a52%\u548c45%\u3002\u867d\u7136\u6bd2\u6027\u589e\u52a0\u4e86\uff0c\u4f46\u672c\u7814\u7a76\u4e2d\u89c2\u5bdf\u5230\u7684\u5e94\u7b54\u7387\u660e\u663e\u9ad8\u4e8e\u5355\u4e00\u836f\u7269\u7684\u5e94\u7b54\u7387\uff0c\u7279\u522b\u662f\u8003\u8651\u5230\u5148\u524d\u63a5\u53d7\u7cfb\u7edf\u6cbb\u7597\u7684\u60a3\u8005\u7684\u79bb\u6563\u6570\u91cf\u3002\u7136\u800c\uff0c\u7531\u4e8e\u6bd2\u6027\uff0c\u8fd9\u4e9b\u7ec4\u5408\u6ca1\u6709\u5f97\u5230\u8fdb\u4e00\u6b65\u7684\u63a8\u52a8\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6b64\u5916\uff0c\u5728Ib\u671f\u7814\u7a76\u4e2d\u5bf9atezolizumab\u548cbevacizumab(\u4e00\u79cd\u76f4\u63a5\u6291\u5236\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u7684\u5355\u6297)\u8fdb\u884c\u4e86\u7814\u7a76(atezolizumab\u6bcf3\u546820 mg\/kg\uff0cbevacizumab\u6bcf3\u546815 mg\/kg)\u300210\u4f8b\u80be\u764c\u60a3\u8005\u7ecf\u7597\u6548\u8bc4\u4f30\uff0cORR\u4e3a40%\u300240%\u7684\u60a3\u8005\u7ecf\u5386SD\u7684\u65f6\u95f4\u5927\u4e8e\u6216\u7b49\u4e8e24\u5468\u3002\u8054\u5408\u7528\u836f\u8010\u53d7\u6027\u826f\u597d\uff0c33%\u7684\u60a3\u8005(4\/12)\u7ecf\u5386\u4e863-4\u7ea7\u7684AEs\u3002<\/p>\n

\u57282017\u5e74\u6ccc\u5c3f\u751f\u6b96\u7cfb\u764c\u75c7\u7814\u8ba8\u4f1a\u4e0a\u63d0\u51fa\u4e86\u4e00\u9879\u7b2c\u4e8c\u9636\u6bb5\u7684\u968f\u673a\u8bd5\u9a8c\uff0c\u5373atezolizumab\u52a0bevacizumab\u4e0eatezolizumab\u4e0esunitinib\u7684\u6bd4\u8f83(IMmotion 150\u8bd5\u9a8c)\u3002\u8fd9\u9879\u8bd5\u9a8c\u62db\u52df\u4e86305\u540d\u4ee5\u524d\u672a\u63a5\u53d7\u6cbb\u7597\u7684\u80be\u764c\u60a3\u8005\uff0c\u5e76\u968f\u673a\u5206\u914d\u5230\u63a5\u53d7\u9759\u8109\u6ce8\u5c04atezolizumab\u52a0bevacizumab\u3001\u5355\u72ec\u63a5\u53d7atezolizumab\u6216\u5355\u72ec\u53e3\u670dsunitinib\uff0c\u76f4\u5230\u75be\u75c5\u8fdb\u5c55\u6216\u4e0d\u53ef\u63a5\u53d7\u7684\u6bd2\u6027\u3002<\/p>\n

\u5728\u80bf\u7624\u8868\u8fbePD-L1\u7684\u60a3\u8005\u4e2d\uff0c\u63a5\u53d7\u53cc\u91cd\u514d\u75ab\u6cbb\u7597\u7684\u60a3\u8005\u7684\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u6bd4\u5355\u7528sunitinib\u7684\u60a3\u8005\u4f4e36%(HR 0.64\uff1b95% CI\uff0c0.38-1.08\uff1bp\u503c0.095)\uff1b\u4e2d\u4f4dPFS\u5206\u522b\u4e3a14.7\u4e2a\u6708\u548c7.8\u4e2a\u6708\u3002\u5728\u603b\u4f53\u4eba\u7fa4\u4e2d\uff0c\u4e0e\u5355\u7528sunitinib\u76f8\u6bd4\uff0c\u4f7f\u7528atezolizumab\u548cbevacizumab\u5e76\u6ca1\u6709\u89c2\u5bdf\u5230PFS\u4f18\u52bf(HR\uff0c1.00\uff1b95% CI\uff0c0.69-1.45)\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6b63\u5728\u8fdb\u884c\u7684\u7b2c\u4e09\u9636\u6bb5IMMotion 151\u7814\u7a76(ClinicalTrials.gov \u6807\u8bc6\uff1aNCT02420821)\u6b63\u5728\u62db\u52df\u53c2\u4e0e\u8005\uff0c\u5728\u540c\u4e00\u4eba\u7fa4\u4e2d\u5bf9\u6bd4atezolizumab\u8054\u5408bevacizumab\u4e0e\u5355\u72ec\u4f7f\u7528sunitinib\u7684\u7597\u6548\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5176\u4ed6\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u548cPD-1\/PD-L1\u6291\u5236\u5242\u7ec4\u5408\u76ee\u524d\u5728\u51e0\u4e2a\u6b63\u5728\u8fdb\u884c\u7684\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u8fdb\u884c\u7814\u7a76(Table 21.1<\/span>)<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
<\/section>\n<\/section>\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

Table 21.1<\/span>\u6b63\u5728\u8fdb\u884c\u7684\u7b2c\u4e00\u7ebfIII\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Pembrolizumab\u662f\u4e00\u79cd\u4eba\u6e90\u5316\u7684PD-1\u5355\u6297\uff0c\u5728\u5305\u62ec\u80be\u764c\u5728\u5185\u7684\u665a\u671f\u5b9e\u4f53\u80bf\u7624\u60a3\u8005\u8fdb\u884c\u4e86I\u671f\u8bd5\u9a8c\uff0c\u76ee\u524d\u6b63\u5728\u4e0e\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u9776\u5411\u836f\u7269\u8054\u5408\u8fdb\u884c\u7814\u7a76\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Pembrolizumab\u4e0eaxitinib\u7684\u8054\u5408\u5e94\u7528\u662f\u57282016\u5e74ESMO\u5927\u4f1a\u4e0a\u516c\u5e03\u7684\u4e00\u9879\u9488\u5bf9\u672a\u63a5\u53d7\u6cbb\u7597\u7684\u665a\u671f\u80be\u764c\u60a3\u8005\u7684Ib\u671f\u7814\u7a76\u3002\u5728ESMO\u4e0a\u62a5\u9053\u4e8652\u540d\u665a\u671f\u80be\u764c\u60a3\u8005\u63a5\u53d7\u4e86axitinib\u8054\u5408Pembrolizumab\u7684\u4e00\u7ebf\u6cbb\u7597\u3002ORR\u4e3a67.3%(35\u4f8b)\uff0c\u5176\u4e2dCR 2\u4f8b\uff0cPR 33\u4f8b\u3002\u521d\u6b65\u5206\u6790\u8868\u660e\uff0c\u8054\u5408\u7528\u836f\u8010\u53d7\u6027\u597d\uff0c\u5bf9\u521d\u6cbb\u7684\u80be\u764c\u60a3\u8005\u6709\u6297\u80bf\u7624\u6d3b\u6027\u3002\u6b63\u5728\u8fdb\u884c\u7684\u8fd9\u79cd\u8054\u5408\u6cbb\u7597\u4e0esunitinib\u5bf9\u7167\u7684\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u5c06\u8bd5\u56fe\u8bc1\u5b9e\u8fd9\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u7ed3\u679c\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6b64\u5916\uff0cpembrolizumab\u548cpazopanib\u7684\u7ec4\u5408\u5df2\u7ecf\u5728\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684I\/II\u671f\u7814\u7a76\u4e2d\u8fdb\u884c\u4e86\u8bd5\u9a8c\u3002\u521d\u6b65\u62a5\u544a\u4e86\u53c2\u52a0I\u671f\u8bd5\u9a8c\u768420\u540d\u60a3\u8005\u7684\u6570\u636e\uff1a\u8054\u5408\u7528\u836f\u5f15\u8d77\u4e86\u663e\u8457\u7684\u809d\u6bd2\u6027\uff0c65%\u7684\u60a3\u8005(20\u4eba\u4e2d\u670913\u4eba)\u51fa\u73b0\u4e863\u7ea7\u6216\u66f4\u9ad8\u7ea7\u7684\u809d\u529f\u80fd\u969c\u788d(\u6240\u6709\u4eba\u90fd\u6062\u590d\u52301\u7ea7\u6216\u66f4\u4f4e)\u3002\u603b\u961f\u5217\u7684ORR\u4e3a40%(20\u4eba\u4e2d\u67098\u4eba)\uff0cpazopanib 800\u6beb\u514b\u7ec4\u4e3a60%\uff0cpazopanib 600\u6beb\u514b\u7ec4\u4e3a20%\u3002pazopanib 800 mg\u7ec4\u67091\u4f8b\u5b8c\u5168\u7f13\u89e3\u3002\u76ee\u524d\u6b63\u5728\u63a2\u7d22\u65b0\u7684\u7ed9\u836f\u65b9\u6848\uff0c\u4ee5pazopanib\u4e0epembrolizumab\u8054\u5408\u4f7f\u7528\u6765\u964d\u4f4e\u809d\u6bd2\u6027\u98ce\u9669\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u4e00\u7ebf\u665a\u671f\u80be\u764c\u7684Ib\u671f\u8bd5\u9a8c\u4e2d\uff0c\u5bf9\u963f\u897f\u66ff\u5c3c\uff08Axitinib\uff09\u4e0e\u6297PD-L1\u963f\u7ef4\u9c81\u5355\u6297\uff08avelumab\uff09\u8054\u5408\u7597\u6548\u8fdb\u884c\u4e86\u8fdb\u4e00\u6b65\u7684\u7814\u7a76\u3002\u57286\u540d\u60a3\u8005\u4e2d\u89c2\u5bdf\u5230\u4e86\u786e\u8ba4\u7684PR\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

pembrolizumab\u548cavelumab\u90fd\u88ab\u8ba4\u4e3a\u662f\u6709\u7597\u6548\u7684\u836f\u7269\uff0c\u672a\u7ecf\u6cbb\u7597\u7684\u665a\u671f\u80be\u7ec6\u80de\u764c\u60a3\u8005 (NCT02853331\u548cNCT02684006)\u7684III\u671f\u8bd5\u9a8c\u6b63\u5728\u8fdb\u884c\u6d4b\u8bd5\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Cabozantinib\u662f\u4e00\u79cd\u53cc\u91cd\u7684\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\/MET\u6291\u5236\u5242\uff0c\u6700\u8fd1\u5728\u4e00\u9879\u968f\u673a\u7684III\u671f\u8bd5\u9a8c\u4e2d\u8bc1\u660e\uff0c\u5728\u4e00\u7ebf\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u9776\u5411\u6cbb\u7597\u8fdb\u5c55\u540e\uff0c\u9664\u4e86\u6539\u5584mRCC\u60a3\u8005\u7684OS\u5916\uff0c\u8fd8\u53ef\u4ee5\u6539\u5584ORR\u548cPFS\u3002<\/p>\n

\u4e34\u5e8a\u524d\u8bc1\u636e\u8868\u660e\uff0cMET\u53ef\u4ee5\u901a\u8fc7\u8c03\u8282PD-L1\u4fc3\u8fdb\u80be\u764c\u7ec6\u80de\u7684\u5b58\u6d3b\u3002\u76ee\u524d\u67ef\u8d5e\u66ff\u5c3c\uff08cabozantinib\uff09\u8054\u5408\u5c3c\u4f0f\u5362\u5355\u6297\uff08nivolumab\uff09\u6216\u4e0eipilimumab\u8054\u5408\u4f7f\u7528\u6cbb\u7597\u6ccc\u5c3f\u751f\u6b96\u7cfb\u7edf\u80bf\u7624\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\u76ee\u524d\u7eb3\u5165\u7684\u60a3\u8005\u6570\u91cf\u6b63\u5728\u589e\u52a0(NCT02496208)\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Lenvatinib\u662f\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u7684\u591a\u9776\u70b9TKI\uff0c\u5177\u6709\u6297FGFR\u3001PDGFR\u3001RET\u548cKIT\u7684\u6d3b\u6027\u3002\u4e00\u9879II\u671f\u968f\u673a\u5f00\u653e\u7814\u7a76\u8c03\u67e5\u4e86150\u4f8b\u80be\u7ec6\u80de\u764c\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597\u65b9\u6848\uff1alenvatinib(24 mg\/d)\u3001\u4f0a\u6ce2\u5229\u83ab(everolimus)(10 mg\/d)\u6216\u8054\u5408\u7528\u836f(lenvatinib 18 mg\/d\u548ceverolimus 5 mg\/d)\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Lenvatinib\u4e0e\u4eba\u6e90\u5316PD-1\u5355\u6297pembrolizumab\u8054\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u76ee\u524d\u6b63\u5728Ib\/II\u671f\u7814\u7a76(NCT02501096)\u4e2d\u8fdb\u884c\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u66ff\u4f0f\u624e\u5c3c\uff08Tivozanib\uff09\u662f\u4e00\u79cd\u6709\u6548\u7684\u3001\u9009\u62e9\u6027\u7684\u4e09\u79cd\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u6291\u5236\u5242\u3002\u5728\u4e00\u9879\u4e0enivolumab\u8054\u5408\u6cbb\u7597\u80be\u764c\u7684I\/II\u671f\u8bd5\u9a8c(\u79f0\u4e3aTiNivo\u8bd5\u9a8c)\u4e2d\uff0c\u6b63\u5728\u8bc4\u4f30\u5728\u9012\u589e\u5242\u91cf\u4e0btivozanib\u4e0enivolumab\u7684\u5b89\u5168\u6027\uff0c\u5047\u8bbe\u7ed3\u679c\u826f\u597d\uff0c\u8bd5\u9a8c\u4e4b\u540e\u5c06\u4ee5\u65e2\u5b9a\u7684\u8054\u5408\u5242\u91cf\u8fdb\u884c\u6269\u5927II\u671f\u961f\u5217\u8bd5\u9a8c(EudraCT2016002310-44)\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728I\u671f\u8bd5\u9a8c\u4e2d\uff0c\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u6291\u5236\u548cPD-1\/PD-L1\u963b\u65ad\u7684\u6d3b\u6027\u6c47\u603b\u5982\u886821.2\u6240\u793a\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
<\/section>\n<\/section>\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

Table 21.2<\/span> \u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u6291\u5236\u548cPD-1\/PD-L1\u62ee\u6297\u5242\u8054\u5408\u5e94\u7528\u5728\u80be\u764cI\u671f\u8bd5\u9a8c\u4e2d\u7684\u6d3b\u6027<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

\u7ed3\u8bba<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

PD-1\u963b\u65ad\u5728\u665a\u671f\u80be\u7ec6\u80de\u764c\u4e2d\u4ea7\u751f\u4e86\u4ee4\u4eba\u9f13\u821e\u7684\u5e94\u7b54\u7387\u3002\u7279\u522b\u662f\u5728CHECKMate 025\u8bd5\u9a8c\u4e2d\uff0c\u4e0eeverolimus\u76f8\u6bd4\uff0cnivolumab\u5df2\u8fbe\u5230\u4e86\u5176\u5728OS\u4e2d\u7684\u4e3b\u8981\u53d7\u76ca\u7ec8\u70b9\uff0c\u6210\u4e3a\u4e00\u79cd\u65b0\u7684\u6cbb\u7597\u6807\u51c6\u3002\u6297PD-1\/PD-L1\u4e0e\u5176\u4ed6\u836f\u7269\u8054\u5408\u6cbb\u7597\u80be\u764c\u7684\u6709\u6548\u7387\u9ad8\u4e8e\u5355\u4e00\u836f\u7269\uff0c\u4f46\u6bd2\u6027\u8f83\u9ad8\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u786e\u5b9a\u54ea\u4e9b\u60a3\u8005\u5c06\u4ece\u8fd9\u4e9b\u6cbb\u7597\u4e2d\u83b7\u5f97\u4e34\u5e8a\u76ca\u5904\u4ecd\u7136\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u4efb\u52a1\uff0c\u4e5f\u662f\u4e00\u4e2a\u6b63\u5728\u79ef\u6781\u7814\u7a76\u7684\u9886\u57df\u3002IHC\u68c0\u6d4bPD-L1\u8868\u8fbe\u5df2\u88ab\u5e7f\u6cdb\u8bc4\u4f30\u4e3a\u4e00\u79cd\u9884\u6d4b\u751f\u7269\u6807\u5fd7\u7269\u3002\u8bb8\u591a\u60ac\u800c\u672a\u51b3\u7684\u95ee\u9898\u4f7f\u5b83\u7684\u4f7f\u7528\u53d8\u5f97\u6df7\u4e71\uff1a\u4e0d\u540c\u7684\u6297\u4f53\uff0c\u786e\u5b9a\u9633\u6027\u7684\u53ef\u53d8IHC\u9608\u503c\uff0c\u5145\u5206\u7684\u7ec4\u7ec7\u51c6\u5907\u548c\u5904\u7406\uff0c\u539f\u53d1\u7076\u548c\u8f6c\u79fb\u7076\u4e4b\u95f4\u7684\u4e0d\u540c\u8868\u8fbe\uff0c\u4ee5\u53ca\u80bf\u7624\u548c\u514d\u75ab\u7ec6\u80de\u67d3\u8272\u7684\u8bc4\u4f30\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u6709\u6548\u6027\u548c\u6bd2\u6027\u7279\u5f81\u4ecd\u7136\u5b58\u5728\uff0c\u4e14\u6709\u4e00\u7cfb\u5217\u60ac\u800c\u672a\u51b3\u7684\u95ee\u9898\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u9996\u5148\uff0cPD-1\u963b\u65ad\u5728\u80be\u764c\u4e9a\u578b\u4e2d\u7684\u4f5c\u7528\u662f\u4ec0\u4e48\uff0c\u4f8b\u5982\u975e\u900f\u660e\u7ec6\u80de\u80be\u764c\u60a3\u8005\uff1f\u975e\u900f\u660e\u7ec6\u80de\u80be\u764c\u60a3\u8005\u5728\u5f88\u5927\u7a0b\u5ea6\u4e0a\u88ab\u6392\u9664\u5728\u4e0a\u8ff0\u8bd5\u9a8c\u4e4b\u5916\u3002\u6700\u8fd1\uff0c\u975e\u900f\u660e\u7ec6\u80de\u80be\u764c\u60a3\u8005\u7684PD-L1\u72b6\u6001\u88ab\u8bc1\u5b9e\u4e0eOS\u76f8\u5173\uff0c\u63d0\u793a\u963b\u65adPD-1\/PD-L1\u8f74\u5728\u8be5\u4eba\u7fa4\u4e2d\u53ef\u80fd\u663e\u793a\u51fa\u6709\u76ca\u7684\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u7b2c\u4e8c\uff0c\u8bc4\u4f30\u6cbb\u7597\u53cd\u5e94\u7684\u4f20\u7edf\u65b9\u6cd5\u4ecd\u7136\u53ef\u4ee5\u9884\u6d4b\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u76ca\u5904\u5417\uff1f\u5728nivolumab\u7684III\u671f\u8bd5\u9a8c\u4e2d\uff0c\u63a5\u53d7nivolumab\u6cbb\u7597\u7684\u60a3\u8005\u4e0e\u63a5\u53d7evolimus\u6cbb\u7597\u7684\u60a3\u8005\u76f8\u6bd4\uff0c\u5728OS\u65b9\u9762\u6709\u663e\u8457\u7684\u76ca\u5904\u3002\u8fd9\u79cd\u5bf9PFS\u7684\u6e29\u548c\u5f71\u54cd\u53ef\u80fd\u662f\u5047\u6027\u8fdb\u5c55\u7684\u7ed3\u679c\uff0c\u5047\u6027\u8fdb\u5c55\u53ef\u80fd\u662f\u7531\u4e8e\u6fc0\u6d3b\u7684\u514d\u75ab\u7ec6\u80de\u5bf9\u80bf\u7624\u7684\u6e17\u900f\u800c\u53d1\u751f\u7684\uff0c\u5e76\u53ef\u80fd\u5bfc\u81f4\u5047\u6027\u8fdb\u5c55\u3002\u5b9e\u4f53\u80bf\u7624\u7684\u514d\u75ab\u76f8\u5173\u53cd\u5e94\u8bc4\u4f30\u6807\u51c6(IRECIST)\u5df2\u7ecf\u88ab\u63d0\u51fa\u6765\u89e3\u51b3\u8fd9\u4e00\u73b0\u8c61\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u7b2c\u4e09\uff0c\u7ee7\u7eed\u514d\u75ab\u6cbb\u7597\u7684\u6700\u4f73\u6301\u7eed\u65f6\u95f4\u4e5f\u662f\u672a\u77e5\u7684\u3002\u4e00\u4e9b\u8bd5\u9a8c\u5728\u75c5\u60c5\u8fdb\u5c55\u6216\u8868\u73b0\u51fa\u4e0d\u8010\u53d7\u65f6\u505c\u6b62\u4e86\u6cbb\u7597\u3002\u5176\u4ed6\u4eba\u5219\u63d0\u51fa\u4e86\u4e00\u4e2a\u9884\u5148\u5b9a\u4e49\u76842\u5e74\u6cbb\u7597\u505c\u6b62\u70b9\u3002\u867d\u7136\u514d\u75ab\u6cbb\u7597\u7684\u53cd\u5e94\u6a21\u5f0f\u4e0e\u4f20\u7edf\u7597\u6cd5\u4e0d\u540c\uff0c\u4f46\u4e00\u4e9b\u60a3\u8005\u5728RECIST\u8fdb\u5c55\u540e\u4e5f\u53ef\u80fd\u53d7\u76ca\u4e8enivolumab\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4e5f\u8bb8\uff0c\u5bf9\u5bbf\u4e3b\u514d\u75ab\u7cfb\u7edf\u548c\u80bf\u7624\u5fae\u73af\u5883\u7684\u66f4\u597d\u4e86\u89e3\u5c06\u66f4\u597d\u5730\u9610\u660e\u54ea\u4e9b\u60a3\u8005\u5229\u7528\u4e86\u8fd9\u4e9b\u6709\u79ef\u6781\u4f5c\u7528\u7684\u836f\u7269\u3002\u8865\u5145\u6027PD-1\u9014\u5f84\u963b\u65ad\u548c\u9776\u5411\u6cbb\u7597\u6216\u5176\u4ed6\u514d\u75ab\u5b66\u836f\u7269\u6709\u53ef\u80fd\u51cf\u5c11\u80bf\u7624\u8bf1\u5bfc\u7684\u514d\u75ab\u6291\u5236\uff0c\u6539\u5584\u8f6c\u79fb\u6027\u80be\u7ec6\u80de\u764c\u60a3\u8005\u7684\u4e34\u5e8a\u9884\u540e\u3002\u9274\u4e8e\u76ee\u524dPD-1\/PD-L1\u6291\u5236\u5242\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u548c\u5b89\u5168\u6027\uff0c\u8054\u5408\u5e94\u7528\u5f88\u53ef\u80fd\u6210\u4e3a\u5173\u952e\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u63a2\u7d22\u65b0\u7684\u836f\u7269\u3001\u7ec4\u5408\u4ee5\u53ca\u53cd\u5e94\u7684\u751f\u7269\u6807\u8bb0\u7269\u7684\u7814\u7a76\u76ee\u524d\u6b63\u5728\u8fdb\u884c\u4e2d\uff0c\u53ef\u80fd\u4f1a\u4e3a\u672a\u6765\u8f6c\u79fb\u6027\u80be\u7ec6\u80de\u764c\u60a3\u8005\u7684\u6cbb\u7597\u63d0\u4f9b\u6307\u5bfc\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u672c\u6587\u7531Oncolab\u5fae\u4fe1\u516c\u4f17\u53f7\u7ffb\u8bd1\u6574\u7406\u81eaOncoimmunology: A Practical Guide for Cancer Immunotherapy\uff0c\u4ec5\u7528\u4e8e\u5b66\u4e60\u4ea4\u6d41\u4f7f\u7528\uff0c\u5982\u9700\u8d2d\u4e70\u539f\u7248\u4e66\u7c4d\u53ef\u70b9\u51fb\u9605\u8bfb\u539f\u6587\u8d2d\u4e70\u3002<\/span>
<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u2014 THE  END \u2014<\/span><\/p>\n


<\/p>\n

\u6765\u6e90 | Oncoimmunology: A Practical Guide <\/span><\/p>\n

for Cancer Immunotherapy<\/span><\/p>\n

\u4f5c\u8005 | <\/span>Annette Paschen and Dirk Schadendorf<\/span><\/p>\n

\u521d\u7a3f\u7ffb\u8bd1 | \u9648\u6653\u610f \u90d1\u68a6\u6021 \u7ae0\u9707<\/span><\/span><\/span><\/p>\n

\u7f16\u8f91\u6392\u7248<\/span> | \u5415\u601d\u8d24<\/span><\/span><\/span><\/span><\/p>\n

\u5ba1\u6838\u4fee\u6539 | \u738b\u5764 \u80e1\u73ca<\/span><\/p>\n

\uff08\u8f6c\u8f7d\u8bf7\u4fdd\u7559\u6b64\u90e8\u5206\u5185\u5bb9\uff09<\/span><\/strong><\/p>\n


<\/p>\n

\u2589  \u5f3a\u70c8\u63a8\u8350<\/strong><\/strong><\/section>\n
\u2589  \u5f80\u671f\u6587\u7ae0\u5408\u8f91<\/strong><\/strong><\/section>\n

\u80bf\u7624\u514d\u75ab\u5b66\u6700\u65b0\u6587\u732e\u6bcf\u6708\u66f4\u65b0<\/span><\/a><\/a><\/a>
<\/strong><\/strong><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057\u7cfb\u5217<\/span><\/a><\/p>\n

\u80bf\u7624\u514d\u75ab\u5b66\u7cfb\u5217<\/span><\/a>
<\/p>\n

ACIR\u6587\u732e\u901f\u9012<\/span><\/a>
<\/p>\n

SCI\u8bba\u6587\u4f5c\u56fe<\/span><\/a>
<\/p>\n

SCI\u8bba\u6587\u5199\u4f5c\u53ca\u6295\u7a3f<\/span><\/a>
<\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0<\/span><\/a>
<\/p>\n

R\u8bed\u8a00\u57fa\u7840\u4e0e\u5355\u7ec6\u80de\u5206\u6790\u5b9e\u6218\u89c6\u9891\u8bfe\u7a0b<\/span><\/a>
<\/p>\n

\u751f\u7269\u5b66\u5b9e\u9a8c\u6280\u672f\u53ca\u5e38\u7528\u8f6f\u4ef6<\/span><\/a>
<\/p>\n

RCIM\u4eea\u5668\u7b80\u4ecb\u53ca\u64cd\u4f5c\u89c6\u9891<\/span><\/a>
<\/p>\n

\u5e38\u7528\u7535\u8111\u8f6f\u4ef6\u4f7f\u7528\u6559\u7a0b<\/a><\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\u2589  OncoLab\u5b9e\u9a8c\u5ba4\u7f51\u7ad9<\/strong><\/strong><\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

\u672c\u516c\u4f17\u53f7\u4e0a\u7684\u5f80\u671f\u6587\u7ae0\u540c\u6b65\u53d1\u5e03\u81f3\u5bf9\u5e94\u7f51\u7ad9OncoLab\u5b9e\u9a8c\u5ba4\u3002<\/p>\n

\u7f51\u7ad9\u81ea\u5e26\u68c0\u7d22\u529f\u80fd\uff0c\u53ef\u4ee5\u6839\u636e\u5173\u952e\u8bcd\u8fdb\u884c\u68c0\u7d22<\/span>\uff0c\u5e76\u4e14\u53ef\u4ee5\u6839\u636e\u65e5\u671f\u53ca\u5185\u5bb9\u5206\u7c7b<\/span>\u8fdb\u884c\u67e5\u770b ,\u5927\u5bb6\u53ef\u4ee5\u6536\u85cf\u65b9\u4fbf\u5728\u7535\u8111\u4e0a\u67e5\u770b\u3002<\/p>\n

\u7f51\u5740\u662f\uff1aoncolab.cn<\/span><\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u2589  OncoLab\u5b66\u672f\u5bfc\u822a<\/strong><\/strong><\/section>\n
\n
\n
\n
\n
\n

\u6b64\u5916\uff0c\u68b3\u7406\u4e86\u4e00\u4e0b\u8fd9\u51e0\u5e74\u6512\u7684\u6536\u85cf\u5939\uff0c\u505a\u4e86\u4e00\u4e2a\u5bfc\u822a\u7f51\u9875\uff0c\u5305\u542b\u5e38\u7528\u7f51\u7ad9<\/span>\u3001\u6587\u732e\u9605\u8bfb<\/span>\u3001\u8bd5\u5242\u8ba2\u8d2d<\/span>\u3001\u57fa\u91d1\u76f8\u5173<\/span>\u3001\u5b9e\u7528\u5de5\u5177<\/span>\u3001\u5e38\u7528\u6570\u636e\u5e93<\/span>\u7b49\u5206\u7c7b\u5185\u5bb9\uff0c\u5e76\u4e14\u6574\u5408\u4e86<\/span>\u767e\u5ea6\u3001\u8c37\u6b4c\u3001\u5fc5\u5e94<\/span>\u4e09\u5927\u641c\u7d22\u5f15\u64ce\u5230\u68c0\u7d22\u5de5\u5177\u4e2d\uff0c\u6b22\u8fce\u6536\u85cf\u6216\u8bbe\u7f6e\u4e3a\u4e3b\u9875\u4f7f\u7528~<\/span><\/p>\n

\u7f51\u5740\u662f\uff1adh.<\/strong><\/span>oncolab.cn<\/span><\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u2589  OncoLab\u77e5\u8bc6\u661f\u7403<\/strong><\/strong><\/section>\n<\/section>\n
\n
\n
\n
\n

OncoLab\u77e5\u8bc6\u661f\u7403\u4e5f\u5df2\u5f00\u901a\uff0c\u5728\u5b66\u4e60\u672c\u516c\u4f17\u53f7\u5185\u5bb9\u7684\u8fc7\u7a0b\u4e2d\u5982\u679c\u6709\u4ec0\u4e48\u9700\u8981\u8ba8\u8bba\u4ea4\u6d41\u7684\u5730\u65b9\u53ef\u4ee5\u5728\u661f\u7403\u53d1\u8868\u7559\u8a00\uff0c\u4e5f\u53ef\u4ee5\u5206\u4eab\u4e00\u4e0b\u81ea\u5df1\u7684\u5b66\u4e60\u5fc3\u5f97\u4f53\u4f1a\uff0c\u5176\u4ed6\u5c0f\u4f19\u4f34\u770b\u5230\u4e86\u53ef\u4ee5\u79ef\u6781\u7559\u8a00\u56de\u590d\uff0c\u6211\u4e5f\u4f1a\u79ef\u6781\u53c2\u4e0e\u5176\u4e2d\uff0c\u5e76\u65f6\u5e38\u653e\u4e00\u4e9b\u5b66\u4e60\u8d44\u6599\u5728\u4e0a\u9762\uff0c\u5e0c\u671b\u5927\u5bb6\u80fd\u591f\u5728\u79ef\u6781\u4ea4\u6d41\u4e92\u5e2e\u4e92\u52a9\u4e2d\u5171\u540c\u8fdb\u6b65~<\/p>\n

\u8be5\u661f\u7403\u7528\u4e8eOncoLab\u516c\u4f17\u53f7\u8bfb\u8005\u4ea4\u6d41\u5b66\u4e60\u4f7f\u7528\uff0c\u6c38\u4e45\u514d\u8d39<\/span>\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n


<\/p>\n

<\/span><\/p>\n

\u5173\u6ce8\u672c\u53f7~<\/span>
<\/p>\n


<\/p>\n

<\/p>\n

\u52a0\u5165\u8bfb\u8005\u4ea4\u6d41\u7fa4~<\/span><\/p>\n

\uff08\u6dfb\u52a0\u8bf7\u5907\u6ce8\u5355\u4f4d\u59d3\u540d\uff09<\/span><\/p>\n


<\/p>\n

<\/p>\n

\u52a0\u5165\u77e5\u8bc6\u661f\u7403~<\/span><\/p>\n


<\/p>\n


<\/p>\n


<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u70b9\u4eae\u8d5e\u4e0e\u5728\u770b <\/span><\/p>\n

\u8ba9\u66f4\u591a\u4eba\u770b\u5230<\/span><\/p>\n

<\/mp-style-type><\/p>\n

\n

\u672c\u7bc7\u6587\u7ae0\u6765\u6e90\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7:OncoLab<\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c21\u7ae0\uff1aPD-1\u963b\u65ad\u5728\u80be\u7ec6\u80de\u764c\u4e2d\u7684\u4f5c\u7528\uff08\u4e0a\uff09 21.4 PD-L1\u4f5c\u4e3a\u9884\u6d4b\u751f\u7269\u6807\u5fd7\u7269 \u7531\u4e8e\u5bf9nivolumab\u7684\u5e94\u7b54\u7387\u7ea6\u4e3a25%\uff0c\u56e0\u6b64\u9700\u8981\u9884\u6d4b\u6027\u751f\u7269\u6807\u5fd7\u7269\u6765\u786e\u5b9a\u54ea\u4e9b\u60a3…<\/p>\n","protected":false},"author":1,"featured_media":4899,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[59],"tags":[],"_links":{"self":[{"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/4903"}],"collection":[{"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/comments?post=4903"}],"version-history":[{"count":0,"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/4903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/media\/4899"}],"wp:attachment":[{"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/media?parent=4903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/categories?post=4903"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/dh.oncolab.cn\/index.php\/wp-json\/wp\/v2\/tags?post=4903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}